| Bidder (Target) | Value in billion U.S. dollars. |
|---|---|
| AstraZeneca (Alexion)** | 39 |
| Gilead Sciences (Immunomedics) | 21 |
| Siemens Healthineers (Vaian Medical Systems)** | 16.4 |
| Bristol-Myers Squibb (MyoKardia) | 13.1 |
| Illumina (Grail)** | 8 |
| Johnson & Johnson (Momenta) | 6.5 |
| Gilead Sciences (Forty Seven) | 4.9 |
| Bayer (Asklepios BioPharmaceutical)** | 4 |
| Sanofi (Principia Biopharma) | 3.7 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
January 2021
More information
Region
Worldwide
Survey time period
2020
Supplementary notes
* Deals can also include M&As of parts/segments/divisions of companies.
Life sciences include: medicinal chemicals and botanical products; pharmaceutical preparations; in-vitro and in-vivo diagnostics; biotechnology, biological products, except diagnostic substances; pharmaceutical wholesale; medical devices and diagnostics; plant sciences.
** Pending as of publication date.
Citation formats
